White Lion Capital reports 5% Akari Therapeutics (AKTX) stake via equity line

Rhea-AI Filing Summary

Akari Therapeutics Plc reports that White Lion Capital LLC has filed as a significant shareholder. White Lion is deemed to beneficially own 7,001,638,477 ordinary shares of Akari, represented by American Depositary Shares, giving it 5.0% of the ordinary shares outstanding as of June 30, 2026.

Each American Depositary Share represents 80,000 ordinary shares. The reported position consists of ordinary shares that may be issued to White Lion under an equity line Common Stock Purchase Agreement, at the determination of Akari. White Lion has sole voting and dispositive power over the reported shares.

Key Figures

Beneficially owned shares: 7,001,638,477 ordinary shares Ownership percentage: 5.0% Shares outstanding: 140,032,769,533 ordinary shares +1 more

4 metrics

Beneficially owned shares 7,001,638,477 ordinary shares Beneficial ownership reported by White Lion Capital LLC

Ownership percentage 5.0% Portion of Akari ordinary shares beneficially owned by White Lion

Shares outstanding 140,032,769,533 ordinary shares Ordinary shares outstanding as of June 30, 2026, reported by Akari

ADS to ordinary share ratio 80,000 ordinary shares per ADS Each American Depositary Share represents 80,000 ordinary shares

Key Terms

American Depositary Shares, equity line Common Stock Purchase Agreement, beneficially owned

3 terms

American Depositary Shares financial

"Ordinary Shares, par value $0. per share, (represented by American Depositary Shares)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

equity line Common Stock Purchase Agreement financial

"Such shares may be issued to the Reporting Person pursuant to an equity line Common Stock Purchase Agreement"

beneficially owned financial

"Amount beneficially owned: The information contained in rows 5 through and including row 11"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 06:51 PM Accepted by SEC EDGAR 08/07/2026 - 06:51 PM Learn about SEC filing dates

FAQ

What percentage of Akari Therapeutics (AKTX) does White Lion Capital report owning?

White Lion Capital reports beneficial ownership of 5.0% of Akari Therapeutics’ ordinary shares, based on 140,032,769,533 ordinary shares outstanding as of June 30, 2026, as reported by Akari.

How many Akari Therapeutics (AKTX) shares does White Lion Capital beneficially own?

White Lion Capital is reported to beneficially own 7,001,638,477 ordinary shares of Akari Therapeutics. These ordinary shares are represented by American Depositary Shares and may be issued under an equity line Common Stock Purchase Agreement.

What is the structure of Akari Therapeutics (AKTX) American Depositary Shares?

Each Akari Therapeutics American Depositary Share represents 80,000 ordinary shares of the company. The reported White Lion position consists of ordinary shares represented by these American Depositary Shares.

On what share count is White Lion’s 5.0% Akari (AKTX) ownership based?

The 5.0% ownership is calculated using 140,032,769,533 Akari ordinary shares outstanding as of June 30, 2026. This outstanding share figure was reported by Akari and used for the beneficial ownership calculation.

How can Akari Therapeutics (AKTX) shares be issued to White Lion Capital?

The 7,001,638,477 ordinary shares may be issued to White Lion Capital under an equity line Common Stock Purchase Agreement, with issuance determined by Akari as the issuer.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Akari Therapeutics Plc

(Name of Issuer)

Ordinary Shares, par value $0.000000005 per share, (represented by American Depositary Shares)

(Title of Class of Securities)

00972G405

(CUSIP Number)

08/07/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00972G405

1

Names of Reporting Persons

White Lion Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,001,638,477.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,001,638,477.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,001,638,477.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: With regard to Items 5, 7, and 9: Consists of 7,001,638,477 of ordinary shares, par value $0.000000005 per share, represented by American Depositary Shares. Each American Depositary Share represents 80,000 ordinary shares. Such shares may be issued to the Reporting Person pursuant to an equity line Common Stock Purchase Agreement between the parties pursuant to the determination of the Issuer. With regard to Item 11: Percentage calculated based on 140,032,769,533 ordinary shares outstanding as of June 30, 2026 as reported by the Issuer.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Akari Therapeutics Plc
(b)	Address of issuer's principal executive offices: 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FLORIDA, 33602.
Item 2.
(a)	Name of person filing: White Lion Capital LLC
(b)	Address or principal business office or, if none, residence: 17631 Ventura Blvd., Suite 1008 Encino, California 91316
(c)	Citizenship: Nevada
(d)	Title of class of securities: Ordinary Shares, par value $0.000000005 per share, (represented by American Depositary Shares)
(e)	CUSIP Number(s): 00972G405
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4.
(b)	Percent of class: The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4.
	(ii) Shared power to vote or to direct the vote: The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4.
	(iii) Sole power to dispose or to direct the disposition of: The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4.
	(iv) Shared power to dispose or to direct the disposition of: The information contained in rows 5 through and including row 11 on the cover page of this Schedule 13G, including the footnote thereto, is incorporated by reference in this Item 4.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

White Lion Capital LLC

Signature:	/s/ Nathan Yee
Name/Title:	Nathan Yee, Managing Partner
Date:	08/07/2026